AIM: £47.70 (+0.7) | Nasdaq: $32.76 (+1.06)
Search
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
BofA Merrill Lynch
CEO Christian Hogg at Annual Health Care Conference
View Webcast
2017 Final Results
Full Year Financial Results
Updates on Key Clinical Programs
Video Webcast
View Event
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
CNBC Power Lunch
CEO Christian Hogg discusses China biotech
Watch Brief Interview
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Innovation Platform
|
4 Jun 2018
Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting
Group
|
11 May 2018
Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
Group
|
26 Mar 2018
2017 Annual Report and Notice of Annual General Meeting
Group
|
12 Mar 2018
Publication of Form 20-F for the Year Ended December 31, 2017
Group
|
12 Mar 2018
Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Current Share Price
London AIM:HCM
£47.70
+0.7 | 18-Jun-2018 | 09:44 BST
Nasdaq:HCM
US$32.76
+1.06 | 15-Jun-2018 | 15:59 EST
Note: 1 Nasdaq share = ½ AIM share
Latest Presentations
4 Jun 2018
ASCO 2018: Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO
4 Jun 2018
ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
17 Apr 2018
AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
23 Mar 2018
ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Latest Reports
Annual Report 2017 (with Form 20-F)
EN
Interim Report 2017
EN
Annual Report 2016 (with Form 20-F)
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Deutsche Bank
Edison (link to research)
Kim Eng Securities
Panmure Gordon
Stifel
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More